VORTIOXETINE HYDROBROMIDE MAOIs can cause serotonin syndrome Can cause nausea and increased risk of bleeding. | Multimodal Antidepressant | VORTIOXETINE HYDROBROMIDE | safe |
VOSEVI Comprehensive clinical and safety monograph for VOSEVI (VOSEVI). | Direct-Acting Antiviral Combination | VOSEVI | caution |
VOSOL Comprehensive clinical and safety monograph for VOSOL (VOSOL). | Otic Anti-infective | VOSOL | caution |
VOSOL HC Comprehensive clinical and safety monograph for VOSOL HC (VOSOL HC). | Otic Anti-infective with Corticosteroid | VOSOL HC | caution |
VOSPIRE ER Comprehensive clinical and safety monograph for VOSPIRE ER (VOSPIRE ER). | Xanthine Bronchodilator | VOSPIRE ER | caution |
VOSTALLY Comprehensive clinical and safety monograph for VOSTALLY (VOSTALLY). | Gene Therapy | VOSTALLY | caution |
VOTRIENT Comprehensive clinical and safety monograph for VOTRIENT (VOTRIENT). | VEGF Receptor Tyrosine Kinase Inhibitor | VOTRIENT | caution |
VOXZOGO Comprehensive clinical and safety monograph for VOXZOGO (VOXZOGO). | C-type Natriuretic Peptide Analogue | VOXZOGO | caution |
VOYDEYA Comprehensive clinical and safety monograph for VOYDEYA (VOYDEYA). | Complement Factor D Inhibitor | VOYDEYA | caution |
VOYXACT Comprehensive clinical and safety monograph for VOYXACT (VOYXACT). | Antineoplastic | VOYXACT | caution |
VPRIV Comprehensive clinical and safety monograph for VPRIV (VPRIV). | Enzyme Replacement Therapy | VPRIV | caution |
VRAYLAR Comprehensive clinical and safety monograph for VRAYLAR (VRAYLAR). | Atypical Antipsychotic | VRAYLAR | caution |
VTAMA Comprehensive clinical and safety monograph for VTAMA (VTAMA). | Aryl Hydrocarbon Receptor Agonist | VTAMA | caution |
VUITY Comprehensive clinical and safety monograph for VUITY (VUITY). | Cholinergic Agonist | VUITY | caution |
VUMERITY Comprehensive clinical and safety monograph for VUMERITY (VUMERITY). | Fumarate Immunomodulator | VUMERITY | caution |
VUMON Comprehensive clinical and safety monograph for VUMON (VUMON). | Topoisomerase II Inhibitor | VUMON | caution |
VUSION Comprehensive clinical and safety monograph for VUSION (VUSION). | Topical Antibiotic | VUSION | caution |
VYALEV Comprehensive clinical and safety monograph for VYALEV (VYALEV). | Antiparkinson Agent | VYALEV | caution |
VYBRIQUE Comprehensive clinical and safety monograph for VYBRIQUE (VYBRIQUE). | Hormonal Contraceptive (Vaginal Ring) | VYBRIQUE | caution |
VYDUO Comprehensive clinical and safety monograph for VYDUO (VYDUO). | Hormonal Contraceptive (Vaginal Ring) | VYDUO | caution |
VYEPTI Comprehensive clinical and safety monograph for VYEPTI (VYEPTI). | CGRP Antagonist (Migraine Prevention) | VYEPTI | caution |
VYFEMLA Comprehensive clinical and safety monograph for VYFEMLA (VYFEMLA). | Intrauterine Device (Hormonal Contraceptive) | VYFEMLA | caution |
VYKAT XR Comprehensive clinical and safety monograph for VYKAT XR (VYKAT XR). | CNS Stimulant (ADHD) | VYKAT XR | caution |
VYKOURA Comprehensive clinical and safety monograph for VYKOURA (VYKOURA). | Hormonal Contraceptive (Vaginal Ring) | VYKOURA | caution |
VYLEESI (AUTOINJECTOR) Comprehensive clinical and safety monograph for VYLEESI (AUTOINJECTOR) (VYLEESI (AUTOINJECTOR)). | Melanocortin Receptor Agonist (HSDD) | VYLEESI (AUTOINJECTOR) | caution |
VYLOY Comprehensive clinical and safety monograph for VYLOY (VYLOY). | Antineoplastic Agent | VYLOY | caution |
VYNDAMAX Comprehensive clinical and safety monograph for VYNDAMAX (VYNDAMAX). | Transthyretin Stabilizer | VYNDAMAX | caution |
VYNDAQEL Comprehensive clinical and safety monograph for VYNDAQEL (VYNDAQEL). | Transthyretin Stabilizer | VYNDAQEL | caution |
VYONDYS 53 Comprehensive clinical and safety monograph for VYONDYS 53 (VYONDYS 53). | Antisense Oligonucleotide (Duchenne Muscular Dystrophy) | VYONDYS 53 | caution |
VYSCOXA Comprehensive clinical and safety monograph for VYSCOXA (VYSCOXA). | Urologic Agent | VYSCOXA | caution |
VYTORIN Comprehensive clinical and safety monograph for VYTORIN (VYTORIN). | Lipid-lowering Combination (Statin + Ezetimibe) | VYTORIN | caution |
VYVANSE Comprehensive clinical and safety monograph for VYVANSE (VYVANSE). | CNS Stimulant (ADHD) | VYVANSE | caution |
VYVGART Comprehensive clinical and safety monograph for VYVGART (VYVGART). | FcRn Antagonist | VYVGART | caution |
VYVGART HYTRULO Comprehensive clinical and safety monograph for VYVGART HYTRULO (VYVGART HYTRULO). | FcRn Antagonist | VYVGART HYTRULO | caution |
VYXEOS Comprehensive clinical and safety monograph for VYXEOS (VYXEOS). | Liposomal Antineoplastic Combination | VYXEOS | caution |
VYZULTA Comprehensive clinical and safety monograph for VYZULTA (VYZULTA). | Prostaglandin Analog (Glaucoma) | VYZULTA | caution |
WAINUA (AUTOINJECTOR) Comprehensive clinical and safety monograph for WAINUA (AUTOINJECTOR) (WAINUA (AUTOINJECTOR)). | Monoclonal Antibody for Severe Asthma | WAINUA (AUTOINJECTOR) | caution |
WAKIX Comprehensive clinical and safety monograph for WAKIX (WAKIX). | Histamine H3 Antagonist (Narcolepsy) | WAKIX | caution |
WAMPOCAP Comprehensive clinical and safety monograph for WAMPOCAP (WAMPOCAP). | Unknown | WAMPOCAP | caution |
Warfarin Contraindicated in most circumstances. Warfarin is a proven human teratogen. Exposure between 6–9 weeks gestation causes Fetal Warfarin Syndrome: nasal hypoplasia, stippled epiphyses, and limb defects in approximately 5% of exposed fetuses. Any trimester exposure carries risk of fetal intracranial hemorrhage due to anticoagulation of the fetal blood. Exception: women with mechanical heart valves may require warfarin due to inadequate LMWH valve protection — this requires individualized multidisciplinary decision-making. | Anticoagulant (Vitamin K Antagonist) | | avoid |
WARFARIN SODIUM A vast number of drugs can increase or decrease INR through various mechanisms Has a narrow therapeutic index and requires frequent INR monitoring to prevent bleeding or clotting. | Anticoagulant (Vitamin K Antagonist) | WARFARIN SODIUM | avoid |
WAYRILZ Comprehensive clinical and safety monograph for WAYRILZ (WAYRILZ). | Unknown | WAYRILZ | caution |
WEGOVY Comprehensive clinical and safety monograph for WEGOVY (WEGOVY). | GLP-1 Receptor Agonist | WEGOVY | caution |
WEGOVY HD Comprehensive clinical and safety monograph for WEGOVY HD (WEGOVY HD). | GLP-1 Receptor Agonist | WEGOVY HD | caution |
WELCHOL Comprehensive clinical and safety monograph for WELCHOL (WELCHOL). | Bile Acid Sequestrant | WELCHOL | caution |
WELIREG Comprehensive clinical and safety monograph for WELIREG (WELIREG). | HIF-2α Inhibitor | WELIREG | caution |
WELLBUTRIN Comprehensive clinical and safety monograph for WELLBUTRIN (WELLBUTRIN). | NDRI Antidepressant | WELLBUTRIN | caution |
WELLBUTRIN SR Comprehensive clinical and safety monograph for WELLBUTRIN SR (WELLBUTRIN SR). | NDRI Antidepressant | WELLBUTRIN SR | caution |
WELLBUTRIN XL Comprehensive clinical and safety monograph for WELLBUTRIN XL (WELLBUTRIN XL). | NDRI Antidepressant | WELLBUTRIN XL | caution |
WELLCOVORIN Comprehensive clinical and safety monograph for WELLCOVORIN (WELLCOVORIN). | Folic Acid Derivative | WELLCOVORIN | caution |
